Eiko Lifesciences Ltd

Eiko LifeSciences Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after a board meeting to approve the un-audited standalone and consolidated financial results for the quarter ended September 30, 2026, the company said in a filing to the BSE Limited.

Eiko LifeSciences Limited announced the appointment of Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as an Additional Director (Independent and Non-Executive) at a board meeting held on August 24, 2026. Mr. Gaikwad’s appointment is up to the date of the company’s ensuing Annual General Meeting, with a subsequent term of 5 years subject to shareholder approval.

Eiko LifeSciences Limited announced the allotment of 3,05,000 equity shares on the conversion of an equal number of warrants, according to a regulatory filing on Tuesday. The shares were issued at a price of Rs 55 per share, including a premium of Rs 45, to Bhavesh Dhirajlal Tanna and V Square Pharmachem Private Limited, who received the shares on preferential basis after paying Rs 41.25 per warrant. The total amount received from the allotment was Rs 1,25,81,250, increasing the company's issued, subscribed, and paid-up equity share capital to Rs 14,65,08,540, consisting of 1,46,50,854 fully paid-up equity shares.

Eiko Lifesciences Ltd share price ticked higher by 1.42% to Rs 49.86 after the company's net profit saw a mild growth of 0.67% to Rs 1.51 crore, while revenue from operations eased by 8.67% to Rs 16.75 crore in Q2FY26 over Q1FY26. The market capitalization of Specialty Chemicals industry group stocks on BSE stood at Rs 5.14 lakh crore, expanding by 15.05%. It has marginally improved by 1.63% over last one week and rose by 11.57% in last one month while the market capitalization of Eiko Lifesciences Ltd has softened by 1% and 0.47% in the same period respectively. Profit before tax (PBT) of Eiko Lifesciences Ltd stood at Rs 2.0 crore in Q2 FY26, surging by 36.05% year-on-year, and slipping 0.99% quarter-on-quarter. EBITDA came in at Rs 2 crore, rallying 22.58% YoY and crashing by 29.30% sequentially. Total expenses slightly declined by 7.60% to Rs 15.07 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 13.94 crore, contracting by 16.33% YoY, while employee benefits expense was at Rs 0.2 crore, slipping by 4.76% YoY. For the TTM ended FY26, revenue from operations jumped by 263.86% to Rs 37.66 crore, while net profit plunged by 164.09% to Rs 2.32 crore, compared to previous TTM. EBITDA saw a sharp decline of 531% to Rs 2.04 crore, and PBT tanked by 162.07% to Rs 3.06 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 2.78 crore in FY26, as against Rs 0.33 crore in FY25. Eiko Lifesciences Ltd dropped 7.32% in last one year, significantly underperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.

Eiko LifeSciences Limited will hold a board meeting on Wednesday, August 12, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing with the BSE Limited. The trading window for company insiders has been closed since July 1, 2026, and will remain so until 48 hours after the financial results are released.

Net profit of Eiko Lifesciences rose 23.81% to Rs 1.30 crore in the quarter ended March 2026 as against Rs 1.05 crore during the previous quarter ended March 2025. Sales rose 62.73% to Rs 18.34 crore in the quarter ended March 2026 as against Rs 11.27 crore during the previous quarter ended March 2025. For the full year,net profit rose 113.27% to Rs 4.50 crore in the year ended March 2026 as against Rs 2.11 crore during the previous year ended March 2025. Sales rose 39.96% to Rs 52.71 crore in the year ended March 2026 as against Rs 37.66 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales18.3411.27 63 52.7137.66 40 OPM %12.3211.62 -14.107.33 - PBDT2.271.55 46 8.133.46 135 PBT2.021.30 55 7.122.72 162 NP1.301.05 24 4.502.11 113 Powered by Capital Market - Live

Eiko Lifesciences will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Net profit of Eiko Lifesciences rose 239.29% to Rs 0.95 crore in the quarter ended December 2025 as against Rs 0.28 crore during the previous quarter ended December 2024. Sales rose 38.49% to Rs 9.57 crore in the quarter ended December 2025 as against Rs 6.91 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales9.576.91 38 OPM %9.096.51 - PBDT1.390.53 162 PBT1.240.38 226 NP0.950.28 239 Powered by Capital Market - Live

Eiko Lifesciences will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live

Eiko Lifesciences announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 7 January 2026.Powered by Capital Market - Live